☆ 4.7 Article

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

FRONTIERS IN PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer The REALITY Randomized Clinical Trial

Yansong Lin et al.

Summary: The study aimed to assess the efficacy and safety of apatinib in patients with progressive locally advanced or metastatic RAIR-DTC. Results showed that apatinib demonstrated significant clinical benefits in terms of prolonged PFS and improved overall survival with manageable safety profile.

JAMA ONCOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

Current practice in patients with differentiated thyroid cancer

Martin Schlumberger et al.

Summary: Considerable changes have occurred in the management of differentiated thyroid cancer (DTC) over the past four decades, with improved diagnostic tools and prognostic classifications available. Low-risk patients make up the majority with good outcomes, while high-risk patients require more aggressive treatment and follow-up due to frequent recurrences.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

Jigang Chen et al.

Summary: The study evaluated the cost-effectiveness of Sacituzumab Govitecan for metastatic triple-negative breast cancer from the perspectives of China and the United States. Results showed that the current price of SG is unlikely to be cost-effective in both countries. Sensitivity analysis indicated that the price of SG has the greatest impact on cost-effectiveness.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Marcia S. Brose et al.

Summary: Patients with radioiodine-refractory differentiated thyroid cancer who have previously undergone VEGFR-targeted therapy and have no available standard of care were evaluated in this study for the tyrosine kinase inhibitor cabozantinib. Results showed that cabozantinib significantly prolonged progression-free survival, potentially offering a new treatment option for these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article Computer Science, Interdisciplinary Applications

survHE: Survival Analysis for Health Economic Evaluation and Cost-Effectiveness Modeling

Gianluca Baio

JOURNAL OF STATISTICAL SOFTWARE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives

Yingjie Zhang et al.

CLINICAL THERAPEUTICS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma

Weiting Liao et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Article Endocrinology & Metabolism

Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Leslie Wilson et al.

THYROID (2017)

Add to Collection

Article Gastroenterology & Hepatology

Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System

Yongrui Bai et al.

GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)

Add to Collection

Article Pharmacology & Pharmacy

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies

Roy Lirov et al.

DRUGS (2017)

Add to Collection

Article Oncology

Cancer Statistics, 2016

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

Add to Collection

Letter Medicine, General & Internal

Lenvatinib in Radioiodine-Refractory Thyroid Cancer

Hyo Jin Lee et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer

Beth A. Fordham et al.

PATIENT PREFERENCE AND ADHERENCE (2015)

Add to Collection

Article Health Care Sciences & Services

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

George Dranitsaris et al.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2015)

Add to Collection

Article Medicine, General & Internal

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose et al.

LANCET (2014)

Add to Collection

Article Health Care Sciences & Services

CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT

Don Husereau et al.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2013)

Add to Collection

Article Health Care Sciences & Services

Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide

Nicholas R. Latimer

MEDICAL DECISION MAKING (2013)

Add to Collection

Article Health Care Sciences & Services

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Patricia Guyot et al.

BMC MEDICAL RESEARCH METHODOLOGY (2012)

Add to Collection

Article Endocrinology & Metabolism

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy

C. Durante et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.